Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04220229 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04220229: Clinical Trial Phase 1 study, sponsored by University of Washington.
NCT04220229 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04220229, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cabozantinib with radiation therapy may make the tumors smaller and reduce the amount of normal tissue that needs to be removed.
Primary Outcome
Cabozantinib treatment begins 8 days prior to initiation of radiation therapy and continues through completion of radiation therapy.
Interventions
- DRUG Cabozantinib S-malate
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 1 |
Why NCT04220229 stopped before completion
NCT04220229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Cabozantinib S-malate is the first listed.
NCT04220229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04220229 about?
NCT04220229 is a clinical study titled "Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities". This phase I/II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving c...
What is the current status of trial NCT04220229?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-06-01. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT04220229?
The interventions under investigation include: Cabozantinib S-malate (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04220229?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04220229's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI